Haemostatic Effects of Recombinant Human Erythropoietin in Chronic Haemodialysis Patients

1989 ◽  
Vol 61 (01) ◽  
pp. 117-121 ◽  
Author(s):  
Chris van Geet ◽  
Didier Hauglustaine ◽  
Luc Verresen ◽  
Marleen Vanrusselt ◽  
Jos Vermylen
Keyword(s):  
Platelet Count ◽  
Recombinant Human Erythropoietin ◽  
Bleeding Time ◽  
Chronic Haemodialysis ◽  
Recombinant Erythropoietin ◽  
The Third ◽  
Human Erythropoietin ◽  
Platelet Number ◽  
Almost All ◽  
And Function

SummaryRecombinant human erythropoietin was administered for up to 40 weeks to nine patients on chronic haemodialysis. From the third week of administration onwards, not only haemoglobin and haematocrit but also the platelet count rose, the latter, however, transiently. Subnormal platelet aggregation before therapy also improved transiently and in parallel with the erythropoietin dosage. The bleeding time normalized in almost all patients. There were no major side-effects. We conclude that recombinant erythropoietin improves haemostasis in chronic haemodialysis patients by increasing the haematocrit and in addition transiently enhances platelet number and function.

Bleeding Time in Rats: A Comparison of Different Experimental Conditions

1982 ◽  
Vol 48 (01) ◽  
pp. 108-111 ◽  
Author(s):  
Elisabetta Dejana ◽  
Silvia Villa ◽  
Giovanni de Gaetano
Keyword(s):  
Platelet Function ◽  
Bleeding Time ◽  
Platelet Dysfunction ◽  
Experimental Conditions ◽  
Platelet Number ◽  
Coagulation Defects ◽  
Tail Tip ◽  
And Function ◽  
Storage Pool Disease ◽  
Type Of Anaesthesia

SummaryThe tail bleeding time (BT) in rats definitely varies according to the method applied. Of the various variables that may influence BT, we have evaluated the position (horizontal or vertical) of the tail, the environment (air or saline), the temperature (4°, 23° or 37° C) and the type of anaesthesia. Transection of the tail tip cannot be used to screen drugs active on platelet function since it is sensitive to coagulation defects. Template BT in contrast is not modified by heparin and is sensitive to defects of platelet number and function (“storage pool disease”, dipyridamole-like drugs, exogenous prostacyclin). In contrast the test fails to detect aspirin-induced platelet dysfunction. The evidence reported indicates that thromboxane A2-prostacyclin balance is not a factor regulating BT. Aspirin treatment however may be a precipitating factor when associated with other abnormalities of platelet function.Template BT is a valid screening test for platelet disorders and for antiplatelet drugs.

Effects of Recombinant Human Erythropoietin in Infants with Very Low Birth Weights

1996 ◽  
Vol 24 (2) ◽  
pp. 190-198 ◽  
Author(s):  
N Samanci ◽  
F Ovali ◽  
T Da͂o͂lu
Keyword(s):  
Recombinant Human Erythropoietin ◽  
Day Treatment ◽  
Haemoglobin Concentration ◽  
The Third ◽  
Human Erythropoietin ◽  
Erythropoietin Production ◽  
End Of Treatment ◽  
Anaemia Of Prematurity ◽  
Oral Supplements ◽  
To Receive

Anaemia of prematurity, a postnatal fall in haemoglobin concentration and haematocrit, is particularly common in those born at less than 32 weeks of gestation. Experimental and clinical data implicate inadequate erythropoietin production as an important reason. In this study recombinant human erythropoietin (r-HuEpo) was used in an attempt to treat or prevent this anaemia and thereby provide an alternative to erythrocyte transfusions. Premature infants (birth weight ≤ 1250 g and gestational age ≤ 32 weeks), who were likely to need transfusions, were randomly assigned to receive 4 weeks of treatment with either subcutaneously administered r-HuEpo (200 U; n = 12) or placebo ( n = 12), three times weekly. All patients had oral supplements of elemental iron at a dose of 3 mg/kg/day. Treatment was started in the third week of life. Reticulocyte counts were significantly raised ( P < 0.05) in the group treated with r-HuEpo at the end of treatment. The neonates in the group treated with r-HuEpo needed fewer erythrocyte transfusions than those in the placebo group during treatment. There were no toxic effects attributable to r-HuEpo. The results indicate that treatment of infants with very low birth weights with r-HuEpo will reduce their need for erythrocyte transfusions

scholarly journals The effect of erythropoietin treatment on left ventricular hypertrophy in haemodialysis patients

2003 ◽  
Vol 3 (4) ◽  
pp. 11-15 ◽  
Author(s):  
Senija Rašić ◽  
Indira Kulenović ◽  
Irfan Zulić ◽  
Azra Haračić ◽  
Mithat Čengić ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Recombinant Human Erythropoietin ◽  
Ventricular Hypertrophy ◽  
Significant Negative Correlation ◽  
Left Ventricular ◽  
Chronic Haemodialysis ◽  
Human Erythropoietin ◽  
Lv Mass ◽  
Erythropoietin Treatment ◽  
Anaemia Correction

Anaemia appears to play an important role in left ventricular (LV) enlargement in chronic kidney disease patients. The objective of this study was to evaluate LV echocardiography changes during anaemia correction with recombinant human erythropoietin(rHu-Epo) in chronic haemodialysis patients (HD pts) with signs of anaemia and LV hypertrophy (LVH). The study included 20 HD pts aged 39,6 +/- 5,3 yrs, with the same condition of HD treatment, anaemia and echocardiographically LVH verified. At the beginning of the rHu-Epo treatment haemoglobin (Hb) level was < 90 g/L and the target Hb level was 110 g/L. Echocardiography was performed at the beginning (baseline) and after six months of rHu-Epo treatment. LVH was defined as LV mass index >100 g/m2 in women and >131 g/m2 in men. We observed significant reduction of LV mass index (LVMI) (mean 26,4%, p=0.008), as well as LV volumen. There was a significant negative correlation between Hb level and LVMI with predictive LVMI reduction of 2,317 g/m2 for each 1g/L rising of mean Hb level. The results of the study confirm the importance of early anaemia correction in haemodialysis patients aimed to improve LV parameters.

scholarly journals Survival of recombinant erythropoietin in the circulation: the role of carbohydrates

Blood ◽  
1989 ◽  
Vol 73 (1) ◽  
pp. 84-89
Author(s):  
MN Fukuda ◽  
H Sasaki ◽  
L Lopez ◽  
M Fukuda
Keyword(s):  
Recombinant Human Erythropoietin ◽  
Binding Protein ◽  
Chinese Hamster Ovary Cells ◽  
Chinese Hamster ◽  
Recombinant Erythropoietin ◽  
Lectin Affinity Chromatography ◽  
Glycoprotein Hormone ◽  
Human Erythropoietin

Recombinant human erythropoietin produced in transfected Chinese hamster ovary cells is glycosylated much the same way as the erythropoietin present in human urine. To determine the role of carbohydrates in the stability of recombinant human erythropoietin in vivo, [125I]-labeled recombinant erythropoietin was intravenously infused into rats. The erythropoietin was slowly cleared from the blood with a half-life of approximately two hours. Asialoerythropoietin, which was produced by treatment of recombinant human erythropoietin with sialidase, was found to be cleared rapidly from circulation within ten minutes. These data suggest that the galactose binding protein of hepatic cells is involved in the clearance of asialoerythropoietin. Erythropoietin also contains N-glycans with a few N-acetyllactosamine repeats, which can be enriched by tomato lectin affinity chromatography. The lectin-bound fraction was cleared to a larger extent than was the unfractionated erythropoietin, while the component that did not bind the lectin was found to be stable in the circulation. Authentic N-acetyllactosamine repeats (polylactosaminoglycans) prepared from erythrocytes were similarly rapidly cleared from the circulation to the liver, and this clearance was inhibitable with asialo-alpha 1- acid glycoprotein. These results suggest that (a) the sialic acid of the recombinant erythropoietin is necessary for this glycoprotein hormone to circulate stably and (b) glycoproteins with more than three lactosaminyl repeat units may be cleared by the galactose binding protein of hepatocytes.

scholarly journals Recombinant human erythropoietin separation using a cation-exchange multimodal adsorbent

2019 ◽  
Vol 12 (1) ◽  
pp. 103-107
Author(s):  
Marta Ostrihoňová ◽  
Jana Adamíková ◽  
Tomáš Molnár ◽  
Monika Antošová ◽  
Milan Polakovič
Keyword(s):  
Cation Exchange ◽  
Chromatographic Separation ◽  
Recombinant Human Erythropoietin ◽  
Batch Adsorption ◽  
Recombinant Erythropoietin ◽  
Optimal Conditions ◽  
Effect Of Ph ◽  
Human Recombinant Erythropoietin ◽  
Human Erythropoietin ◽  
Nacl Concentration

Abstract This work deals with the capture of human recombinant erythropoietin (rhEPO) from a mixture of proteins in a concentrated postcultivation supernatant. Cation-exchange multimodal adsorbent Capto MMC ImpRes was selected as potential chromatographic separation material. Its equilibrium properties were investigated in batch adsorption experiments. The effect of pH in the range of 5.5—7.5 and NaCl concentration in the range of 0—300 mM on the adsorption of rhEPO and contaminant proteins was examined. Optimal conditions found in these equilibrium experiments were applied to rhEPO adsorption in a chromatographic column. Several experiments were carried out at different elution conditions to optimize the rhEPO yield and selectivity.

Sign in / Sign up

Export Citation Format

Share Document